MTOR and breast carcinoma: Current therapeutic strategies for HR+ breast cancer comprise endocrine therapy, mTOR, or cyclin-dependent kinase 4/6 (CDK4/6) inhibition et al. Nevertheless, disease progression, metastasis, and drug resistance eventually develop [2].